Evidence map›Paper›PMID 39333349›Full record

ArticlePhotochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology2024

Visible light potentiates rapid cell destruction and death by curcumin in vitro.

Joseph A DePasquale

Abstract read
PubMed Publisher
In one paragraph

Article in Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Joseph A DePasqualeMorphogenyx Inc, PO Box 717, East Northport, NY, 11731, USA. jadepasquale@morphogenyx.com.ORCID http://orcid.org/0000-0002-6944-756X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Curcumin, a small molecule derived from the plant Curcuma longa, is a pleiotropic agent with widely varying pharmacological activities attributed to it. In addition to its anti-cancer activity curcumin is also known to be cytotoxic upon photoactivation. Time-lapse DIC and correlative fluorescence microscopy were used to evaluate the effects of curcumin, combined with continuous exposure to visible light, on cellular components of RTG-2 cells. Curcumin combined with visible light resulted in rapid and dramatic destruction of cells. F-actin and microtubule cytoskeletons were drastically altered, both showing fragmentation and overall loss from cells. Nuclei exhibited granulated nucleoplasm, condensed DNA, and physical shrinkage. Mitochondria rapidly fragmented along their length and disappeared from cells. Plasma membrane was breached based on lipophilic dye staining and the entrance of otherwise impermeant small molecules into the cell. Grossly distorted morphology hallmarked by significant swelling and coarse granulation of the cytoplasm was consistently observed. All of these effects were dependent on visible light as the same cellular targets in curcumin-treated cells outside the illuminated area were always unperturbed. The combination of curcumin and continuous exposure to visible light enables rapid and irreversible cellular destruction which can be monitored in real-time. Real-time monitoring of this structural disintegration suggests a new approach to applying curcumin in photodynamic treatments, where the progression of cell and tissue destruction might be simultaneously evaluated through optical means.

Indexed as

CurcuminLightAnimalsCell DeathHumansMitochondriaCurcumin

Identifiers

PMID39333349

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.